Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06641414 · ClinicalTrials.gov registry record · Phase 3
Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).
A Phase 3 study of Higher-risk Myelodysplastic Syndrome, sponsored by Ascentage Pharma Group.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 490
- Enrollment target
- 2
- Study locations
NCT06641414 is a Phase 3 study of Higher-risk Myelodysplastic Syndrome that is actively recruiting participants, run by Ascentage Pharma Group. The registered enrollment target is 490 participants. The trial reports 2 study locations across 2 states.
The verdict
NCT06641414, a Phase 3 study of Higher-risk Myelodysplastic Syndrome, is actively recruiting participants, sponsored by Ascentage Pharma Group.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 490 participants
- Enrollment target
- 2
- Study locations
Study Summary
A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.
Conditions Studied
Interventions
- OTHER Placebo
- DRUG Lisaftoclax (APG-2575)
- DRUG Azacitidine Injection
Study Locations (2)
Texas
- MD Anderson Cancer Center - Houston
Beijing Municipality
- Peking University People's Hospital - Beijing
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 490 participants |
| Start Date | 2025-01-22 |
| Est. Completion | 2029-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06641414
The ClinicalTrials.gov registry entry for NCT06641414 describes a study currently listed as recruiting, categorized as Phase 3. The registered enrollment target is 490 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ascentage Pharma Group, which has 15 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Higher-risk Myelodysplastic Syndrome appearing as the primary indexed condition, and to 3 interventions - of which Placebo is the first listed.
NCT06641414 reports 2 study locations spanning 2 distinct geographic areas - top geographies include Texas, Beijing Municipality.
Frequently Asked Questions
What is clinical trial NCT06641414 about?
NCT06641414 is a clinical study titled "Lisaftoclax (APG-2575) Combined With Azacytidine (AZA) in the Treatment of Patients With Higher-risk Myelodysplastic Syndrome (GLORA-4).". A global multicenter, randomized, double-blind, placebo-controlled, pivotal phase III study. To evaluate overall survival (OS) of Lisaftoclax (APG-2575) combined with azacitidine (AZA) vs. placebo combined with azacitidine in newly diagnosed patients with HR-MDS.
What is the current status of trial NCT06641414?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 490 participants. The study started on 2025-01-22. Estimated completion is 2029-12.
What conditions does trial NCT06641414 study?
This clinical trial studies the following conditions: Higher-risk Myelodysplastic Syndrome.
What interventions are being tested in trial NCT06641414?
The interventions under investigation include: Placebo (OTHER), Lisaftoclax (APG-2575) (DRUG), Azacitidine Injection (DRUG).
Who is sponsoring clinical trial NCT06641414?
This trial is sponsored by Ascentage Pharma Group, which has 15 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06641414 being conducted?
This trial has 2 study locations across Texas, Beijing Municipality. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Higher-risk Myelodysplastic Syndrome
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.